Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Neonatal Abstinence Syndrome
JAMA 319:1362-1374, Wachman, E.,et al, 2018
Recognition and Management of Withdrawal Delirium
NEJM 371:2109-2113, Schuckit, M.A., 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Opiates and Synthetic Analgesic Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1201, Ropper, A.H.,et al, 2014
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005